ISSUE 2
S S
UNDAY, APRIL 6,
2025
AAN Vision
To be indispensable to our members
AAN Mission
To enhance member career fulfillment and promote brain health for all
American Academy of Neurology
201 Chicago Avenue
Minneapolis, MN 55415 USA
Phone: (800) 879-1960 (Toll Free) or (612) 928-6000 (International) Fax: (612) 454-2746
Email: memberservices@aan.com
Website: AAN.com
AAN Chief Executive Officer: Mary E. Post, MBA, CAE
Managing Editor: Angela M. Babb, MS, CAE, APR
Editor: Val Lick
Writers: Ryan Knoke, Sarah Parsons
Designer: Andrew Imholte, Jim Hopwood
Photography: Will Evans
Annual Meeting Daily is published by the American Academy of Neurology.
The American Academy of Neurology’s registered trademarks and service marks are registered in the United States and various other countries around the world.
11:30 a.m.–4:00 p.m. Opening Luncheon 11:30 a.m.–1:30 p.m.
Society Spotlight | Scientific Sessions
1:00 p.m.–3:00 p.m.
Education Courses 7:00 a.m.–9:00 a.m. Poster Session 2 8:00 a.m.–9:00 a.m.
Poster Session 3 11:45 a.m.–12:45 p.m.
Medical Student Symposium 12:30 p.m.–5:00 p.m.
Industry Therapeutic Updates 11:45 a.m.–12:45 p.m.
Education Courses 1:00 p.m.–5:30 p.m.
Neuroscience in the Clinic | Scientific Sessions
3:30 p.m.–5:30 p.m.
Annual Meeting Party 7:00 p.m.–10:00 p.m.
Poster Session 4
5:00 p.m.–6:00 p.m.
Exhibit hall packs a punch with week of jam-packed happenings
Kicks off today with opening luncheon
The Annual Meeting’s super popular Exhibit Hall Opening Luncheon starts today at 11:30 a.m., kicking off the next four days of happenings you won’t want to miss! Open daily from 11:30 a.m.–4:00 p.m. (and through 6:00 p.m. on Monday), this year’s exhibit hall promises to be jam packed with countless opportunities to join forces with your friends and colleagues to experience interactive exhibits, events, and other fun experiences. Learn about the latest advancements in patient care, find products that add efficiencies to your practice, and gather resources that assist patients and caregivers. Building a trip to the exhibit hall into your Annual Meeting schedule is the only way to get new information from the diverse, neurology-focused companies that are here to help you and your patients. And don’t forget to harness the power of the AAN Conferences mobile app to help you find more details and locations about specific exhibitors!
Swoop on in to:
• Get an incredible personalized SketchBot Mosaic portrait—artistically drawn completely by a robot in less than 45 seconds! Take your sketch home + get it emailed to you and displayed on a digital screen in the Sails Pavilion.
• Regional Injection Training and Education program, an interactive, hands-on cadaver workshop, presented by AbbVie Medical Institute. The program will occur in a mobile lab located directly in the exhibit hall and will provide injection training and discussions about real-world challenges in adult spasticity, cervical dystonia, and chronic migraine management. Registration for these sessions must be done in person. Registration opens at 8:00 a.m. today. Visit the cadaver workshop registration booth located in Exhibit Hall D.
• Visit the Puppy Park, where Puppy Love will be providing playful four-legged friends from local rescue partners to help relieve stress and put a smile on your face!
• Grab a cup of specialty coffee at the Buzz Cafes. Whether you prefer regular or decaf, vegan or half & half, there’s a coffee beverage for you!
• Relax and recharge your devices—and yourself—while connecting to colleagues from the variety of comfortable seating options and locations in the Exhibit Hall Charging Lounges.
• Visit the Innovation Hub with physician talks, paint and wine, and VR!
• Check out the latest research at the Poster Hall.
• Explore booths organized in thematic neighborhoods, including the new Digital Health Neighborhood, an area dedicated to the latest innovative advancements in digital health technology.
• Learn about pipeline products, new notable companies, and more at the Exhibitor Presentation Stage.
• Enjoy food and fun at the Networking Crawl on Monday from 4:00 p.m.–6:00 p.m.
Remember: Your exhibit hall ‘passport’ is your ticket to win prizes!
Don’t forget to complete your exhibit hall passport for a chance to win prizes, including a grand prize drawing of a 2026 Annual Meeting registration and a three-night stay in an AAN block hotel—compliments of the Academy. Passports are available in the exhibit hall.
CONTROVERSIES IN NEUROLOGY
PRESIDENTIAL PLENARY :
Advocacy is one of the most important things we do as the AAN. Learn why at today’s Presidential Plenary, 9:15 a.m.–12:00 p.m. in Ballroom 20.
The AAN—and thousands of its members—advocate constantly for neurology. Flying members to the US Capitol for events like Neurology on the Hill, providing advocacy leadership programs like the Palatucci Advocacy Leadership Forum, contacting legislators, and using tools like BrainPAC are just a few of the ways the AAN works toward positive change.
“As neurologists and neuroscience professionals, we are the experts in brain health—and we are the essential voice in advocating for our field and our patients,” said AAN President Carlayne E. Jackson, MD, FAAN. “Our advocacy gives us a crucial voice in the laws and regulations that impact our work and people’s lives, and it ensures we are doing all we can to promote brain health for all.”
Jackson will give a lecture on “Advocacy in Action” today as part of the Presidential Plenary, an annual session featuring the AAN’s premier lecture awards as well as addresses by top researchers on some of the year’s most significant neurology findings.
Other speakers will include Hope M. O’Brien, MD, MBA, FAAN; Brett M. Kissela, MD, MS, FAAN; Sarah Song, MD, MPH, FAAN; Eddie L. Patton, MD, MS, MBA, FAAN; Roy H. Hamilton, MD, MS, FANA, FAAN; Anne M. Connolly, MD, FAAN; and Merit E. Cudkowicz, MD, MSc, FAAN.
Advocacy Day Sessions
Today is Advocacy Day at the Annual Meeting! Visit the Practice and Policy Hub in 20D Lobby for a full day of advocacy workshops, panels, and ways to connect with fellow advocates and AAN staff.
12:30 p.m.–1:15 p.m. Full-time Heroes: Integrating Advocacy into Your Daily Mission
Learn the benefits of advocacy and how to incorporate it into your work, whether in a hospital, academia, or private practice.
1:30 p.m.–2:15 p.m. Unlocking the Capitol: Neurology Advocates Meet Policymakers
Equip yourself with the skills to engage with policymakers and navigate formal settings, including meetings at district and DC offices.
Following the workshop, the Kenneth Viste Award for Patient Advocacy will be presented to Kapil Arya, MBBS, DA, FAAP, FACNS, FAAN.
2:30 p.m.–3:15 p.m. Supercharged Trainee: Powering Up Your Advocacy Skills
Understand the importance of advocacy as a student or trainee and discover opportunities available through the AAN.
3:30 p.m.–4:15 p.m BrainPAC: The Superpower Behind Every Advocate & How to Activate It
Become a BrainPAC champion by mastering peer-to-peer fundraising and engaging policymakers through the political process.
4:30 p.m.–5:15 p.m. Policy Powerhouse: Crafting the Blueprint for Change
Take the opportunity to learn how policy is crafted and gain insights into the process surrounding regulations and what you can do to make a difference.
AAN MEMBERS PUT ‘ADVOCACY IN ACTION’
Presidential Plenary Lecture Awards
The Presidential Plenary features the AAN’s premier lecture awards for clinically relevant research, providing an opportunity to learn from top researchers. Following the “Advocacy in Action” Presidential Lecture, the plenary includes:
H. Houston Merritt Lecture: Rewiring the Mind: Noninvasive Brain Stimulation Approaches to Translational Neurorehabilitation
Sidney Carter Award in Child Neurology: Corticosteroids: The First Neuromuscular Treatment Hammer I Was Given
AAN Lifetime Achievement Award for Clinically Relevant Research: Fast-tracking Discovery in ALS: Collaboration, Innovation, and Open Science
Roy H. Hamilton, MD, MS, FANA, FAAN University of Pennsylvania Perelman School of Medicine
Anne M. Connolly, MD, FAAN Nationwide Children’s Hospital
Merit E. Cudkowicz, MD, MSc, FAAN Massachusetts General Hospital
Celebrate together tonight at the Annual Meeting Party!
Join your friends and colleagues—and a certain brain-shaped mascot—tonight in San Diego’s vibrant Gaslamp Quarter, right across from the convention center. From L Street and the Gaslamp Quarter Sign to J Street, 5th Avenue will be your playground for music, dancing, games, and delicious food and drinks!
The Annual Meeting Party will run from 7:00 p.m. to 10:00 p.m. Your attendee badge is your ticket for complimentary entry, so make sure to wear it! To bring a guest (21+), visit Registration to purchase a
guest ticket for $125 by 6:00 p.m. Guest tickets will be available for purchase at the party, but the price will increase to $150. Regular shuttle hours will be extended for transportation to and from shuttledesignated hotels, with final departure from the party taking place no later than 10:30 p.m.
This is your chance to unwind during the meeting and enjoy a classic block party, featuring some of the best this historic San Diego neighborhood has to offer!
DISCOVER THE DIAGNOSTIC POWER OF SKIN
Gain key pathological insights for patients facing challenging diagnoses using three simple skin biopsies. The Syn-One Test provides visual evidence of a synucleinopathy by detecting abnormal synuclein within cutaneous nerve fibers, helping clinicians diagnose Parkinson’s disease, dementia with Lewy bodies, and related disorders.
With >95% sensitivity and specificity1, the Syn-One Test has been shown to increase diagnostic confidence and support more personalized treatment plans.2
Visualize Abnormal Synuclein in Dermal Nerves
Learn more about the Syn-One Test at cndlifesciences.com
Swoop in to the AAN Awards Showcase in the Sails Pavilion to recognize and celebrate our very own neurology heroes—the recipients of prestigious AAN awards! While there, share your own super cool, super fun photos on social media using #AANAM and #AANScience The Awards Showcase is open through the remainder of the meeting, and other award recognitions may be found in various spots across the convention center.
Business Administrator Day, a program packed with learning, dialogue, and networking, is back for its third year! Business administrators attending the Annual Meeting can join in Monday at the Hilton San Diego Bayfront in Indigo C starting at 8:00 a.m. Sessions will focus on the latest trends in health care management, strategies for creating sustainable and patientcentered practices, and the importance of maintaining worklife balance in a demanding industry. During the program, administrators will have the opportunity to relax with their peers over an exclusive, catered lunch.
Driving Change for Anti-amyloid Therapy Implementation: Overcoming Challenges Across Practice Settings
Monday, April 7th, 2025 ● 11:45 AM – 12:45 PM
Location: Salon 6C
Three practicing neurologists with experience treating patients with anti-amyloid monoclonal antibodies (mAbs) will discuss the following topics:
David Weisman, MD
Director of Clinical Research
Abington Neurological Associates Abington, PA
Guidance for preparing integrated delivery networks for implementation of mAb therapies 1
Early insights from consensus recommendations for use of anti-amyloid mAbs within private practice settings 2
Practical considerations for accessing and using expert-developed resources 3
Head of Clinical Trials Program Cleveland Clinic Lou Ruvo Center for Brain Health Cleveland, OH
Associate Professor of Medicine/Neurology Cleveland Lerner College of Medicine Case Western Reserve University
Jose Soria-Lopez, MD
Practicing Neurologist and Director of Clinical Research
The Neuron Clinic, San Diego, CA
Adjunct Assistant Clinical Professor Department of Neurosciences University of California, San Diego
We look forward to seeing you at this exciting symposium!
2025–2027 AAN Officers and Board approved at Business Meeting
AAN members elected the slate of officers and directors nominated for election at Saturday’s Business Meeting. The entire board for the 20252027 term, including ex officio AAN directors and AAN Institute directors, is listed below. The new term begins on April 10. Congratulations and thank you, AAN leaders!
AAN Officers
• Natalia S. Rost, MD, MPH, FAAN, FAHA, President
• Lyell K. Jones, Jr., MD, FAAN, President Elect
• Charles C. Flippen II, MD, FAAN, Vice President
• Elaine C. Jones, MD, FAAN, Secretary
• Lily Jung Henson, MD, MMM, FAAN, Treasurer
• Carlayne E. Jackson, MD, FAAN, Immediate Past President
AAN Directors
• Wayne E. Anderson, DO, FAHS, FAAN
• Jennifer Bickel, MD, FAAN
• Gregory E. Cooper, MD, PhD, FAAN*
• Gregory J. Esper, MD, MBA, FAAN
• Larry B. Goldstein, MD, FAAN, FAHA
• Sarah Jane Hon, DO, MBA, FAAN*
• Michael E. Markowski, DO, FAAN*
• Jeffrey C. McClean II, MD, FAAN
• José H. Posas, MD, FAAN
AAN Ex Officio Directors
• Bruce H. Cohen, MD, FAAN – Chair, Advocacy Committee
Bylaws
The following amendments to the AAN Bylaws were approved at the Business Meeting:
• Ex officio voting members of AAN Board to include chairs of the AAN’s “Strategic Committees.” Strategic Committees are committees, designated by the AAN Board of Directors, that inform and lead on the AAN’s long-term vision and strategic plan.
• Allowing members who have obtained the newly announced Distinguished Colleague of the AAN (“DAAN”) designation to vote and hold elected office in the AAN.
• Nimish A. Mohile, MD, FAAN – Chair, Diversity, Equity, and Inclusion Committee
• David A. Evans, MBA* – Chair, Brain Health Committee
• Melissa Yu, MD, FAAN* – Chair, Medical Economics and Practice Committee
• Maisha T. Robinson, MD, MS, FAAN – Chair, Member Engagement Committee
• José G. Merino, MD, MPhil, FAHA, FAAN – Chair, Publications Committee
• Mary E. Post, MBA, CAE – Chief Executive Officer, AAN (nonvoting)
AANI Officer
• Brett M. Kissela, MD, MS, FAAN – Secretary/Treasurer
AANI Ex Officio Directors
• Paul M. George, MD, PhD, MSE, FAAN – Chair, Science Committee
• Joseph I. Sirven, MD, FAAN – Chair, Education Committee
• Anup D. Patel, MD, FAAN* – Chair, Quality Committee
Today’s power-packed AAN Conferences mobile app tip: plan your schedule
The powerful AAN Conferences mobile app makes it easy to plan your meeting schedule. Here’s how:
• Select “Program Search” from the main lobby/home screen of the app.
• Select a program, then choose “Add to my schedule.”
• To find all of your selected programs, look under “My Meeting” and then “My Schedule.”
• Any programs you save into “My Schedule” will also appear in the desktop platform and vice versa.
Bonus tip:
You can also download your schedule to sync with your calendar. Want to share an event or your schedule with someone else? You can email it to them using the “Email My Meeting Info” function within “My Meeting.”
3 Clarity quotient, e.g., in an EEG, EMG,
Today’s crossword: Test your neurology know-how!
Take a break to follow these clues and solve today’s crossword puzzle, created by neurologist Sarah Levy, PhD. Find her crosswords in each issue of Annual Meeting Daily! Solutions are on page 27.
1 First responder antibody in an immune response
Bilateral ON's antibody suspect
Don’t have the app yet? Download it today or visit AAN.com/AMOnline for more information.
Need mobile app support? Stop by Meeting Information and Tech Support in B Lobby and near Ballroom 20.
5 Logical prefix here at the AANAM 6 MRI sequence that is SWI’s quantitative
2 .0001 Tesla = 1
3 Clarity quotient, e.g., in an EEG, EMG, MRI 4 Bilateral ON's antibody suspect
How can you access the meeting’s real-time translation technology?
To take advantage of the Annual Meeting’s live AI translation feature, simply scan the QR code on your program’s walk-in slide or click the link in the session listing within the mobile app. You’ll go straight to the Wordly site, where you can choose from 60+ transcription languages, switch between languages at any time, or select audio translation.
Academy joins forces with industry to create super Annual Meeting experience
The AAN has long recognized the power and value of meaningful collaborations with industry, and the Industry Roundtable (IRT) is the AAN’s corporate membership program for companies wishing to deepen our mutual relationship by sharing vision, intellect, and financial resources in our shared pursuit of brain health for all.
While the IRT is active year-round, member companies are particularly engaged at the AAN Annual Meeting, joining forces with the Academy to improve the Annual Meeting experience for all attendees through the valuable support of continuing medical education courses, in-kind donations for workshops, contribution of high-quality research to the scientific program, sponsorship of the Run/Walk for Brain Health, and investment in the future of neurology by supporting the AAN Leadership Development Programs.
Visit the Industry Lounge in room 21 to learn more about the Industry Roundtable and how your company can deepen its engagement with the AAN!
Thank you to the following 2025 Industry Roundtable members*
$75,000 Members
AbbVie
Acadia Pharmaceuticals
Alexion, AstraZeneca Rare Disease
Amgen
argenx
Biogen
Bristol Myers Squibb/ Johnson & Johnson Alliance
Eisai
Eli Lilly
EMD Serono
Genentech
Lundbeck
Novartis Pharmaceuticals
Novo Nordisk
Pfizer
Sanofi
Takeda Pharmaceuticals
UCB, Inc.
Viatris
$50,000 Members
Bristol Myers Squibb
Harmony Biosciences
Supernus Pharmaceuticals
TG Therapeutics
$25,000 Members
Alnylam Pharmaceuticals
Amneal Specialty, a division of Amneal Pharmaceuticals LLC
Annexon Biosciences
AstraZeneca
Axsome Therapeutics
Bayer
C2N Diagnostics
Illumina
Ionis Pharmaceuticals
Ipsen Biopharmaceuticals
Johnson & Johnson
Neurocrine Biosciences
Octapharma
PTC Therapeutics
Roche Sandoz
Xenon Pharmaceuticals
$10,000 Members
Cartesian Therapeutics
Catalyst Pharmaceuticals
Immunovant
Praxis Precision Medicines, Inc
SpringWorks Therapeutics
The Global CEO Initiative on Alzheimer’s Disease
*As of March 13, 2025
Medical students: What’s your neurology superpower? Explore various subspecialty areas while connecting with residents and neurologists at today’s Medical Student Symposium from 12:30 p.m. to 5:00 p.m. in the Hilton San Diego Bayfront Sapphire Ballroom. Gain an understanding about careers in neurology, discover the various subspecialty areas in neurology, and network with residents and neurologists.
The event will kick off with a luncheon, where medical students will be seated at a table with a neurologist and resident/fellow. A lively discussion will follow with moderators leading panel discussion on “Journeys in Neurology.”
From 3:00 p.m. to 5:00 p.m., students will meet and speak with neurologists representing over 20 subspecialties who will share information about their subspecialty, their education and career paths, and how they maintain a work-life balance.
DEP: YY(Project Name) Ad—Half Page Horizontal> NJ, NCP Placed in Neurology Journal, or Neurology Clinical Practice
8.25 x 5.4375 +0.125 bleed, 4C
AAN Online Learning
Pablo R. Castillo, MD, FAAN, AAN Education Committee member, and Andrea Lendaris, MD, MS, AAN Pipeline Committee member, field questions on vascular neurology.
TODAY’S HUB HEROICS
Unleash your inner hero at Annual Meeting Hubs!
Prepare to step out of the traditional classroom into the dynamic world of Annual Meeting Hubs. These extraordinary learning opportunities are your chance to connect, collaborate, and learn through unconventional methods. Hubs will empower you to bring fresh perspectives and innovative approaches back to your career, patients, and community. Get ready to soar to new heights and make a heroic impact! Here are today’s highlights:
Leadership University 5B
The Power of Storytelling: A Skill to Inspire and Influence
1:00 p.m.–2:00 p.m.
Get inspired by tales of how storytelling can boost your effectiveness and help convince others to support your cause.
Practice and
20D Lobby
Unlocking the Capitol: Meet Policymakers
1:30 p.m.–2:15 p.m.
Get ready to engage with advocacy priorities at meetings
BrainPAC: The Superpower Advocate and How
3:30 p.m.–4:15 p.m.
Your roadmap to becoming strategies in peer-to-peer engages policymakers
Academic Hub
27 Lobby
The Role of General Neurologists in Academic Neurology
12:00 p.m.–12:45 p.m.
Over the last decades, the increasing subspecialization in neurology has led to a reduction in the number of general neurologists and, in some academic institutions, a lack of recognition of the role of general neurologists in clinical care and the educational and academic mission. This presentation will discuss the increasingly important role that general neurologists can play in academic institutions; ways that chairs can use general neurologists in the clinical, academic, and educational missions of the department; and how general neurologists can position themselves for success in the academic environment.
HeadTalks
D Lobby
NeuroHeroes Runway
4:45 p.m.–5:30 p.m.
Are you ready to step into the spotlight and discover your signature superhero style? Get ready to embrace the hidden superpower of fashion to boost your confidence, express your personality, and make a lasting impression in your professional and personal life—with a touch of neurologist-inspired flair!
and Policy Hub
Capitol: Neurology Advocates Policymakers with your policymakers in support of the AAN’s meetings at their district and DC offices. Superpower Behind Every How to Activate It
becoming a BrainPAC champion! Learn the best peer-to-peer fundraising and discover how the AAN to advance brain health and neurology.
Research
Hub 11B
Open Access—How to Select Open Access Publication Options and NIH Requirements
2:00 p.m.–2:30 p.m.
Learn from experts regarding selecting open access publication options and how to comply with NIH requirements if your work is funded.
Trainee
Hub Sails Pavilion: Cityside Resident/Fellow Networking with Faculty
2:30 p.m.–3:30 p.m.
Residents and fellows will have an opportunity to connect with and ask questions of graduate medical education faculty and attendings in this speed networking session.
Office Hours
4:30 p.m.–5:30 p.m.
Trainees can drop by to get questions about the Annual Meeting answered, find resources, go over your CV, or connect with neurologists. Look for office hours each day of the meeting.
HUB HEROICS CONTINUED
Innovation Hub Exhibit Hall BCD
Daily Paint and Wine Sessions
12:00 p.m. and 2:00 p.m.
Let your creativity soar by joining one of these popular sessions. Don’t miss out—they fill up fast!
Wellness Hub
Sails Pavilion: Bayside
Neuro-fiber Arts: Embroider Your Cape and Mask!
12:00 p.m.–12:45 p.m.
Join fiber crafters and neurologists as they teach you to embroider a neuron on your own AAN-green superhero cape! Lealani M. Acosta, MD, MPH, FAAN, will demonstrate the brain-themed hats she has knitted and crocheted—including Phineas Gage’s skull, complete with tamping rod—and Allison L. Christy, MD, PhD, FAAN, will show neurons she has painted and embroidered on dresses and fabrics to inspire you to go forth and create your own neurological fiber artwork. Ikigai: Finding Your Purpose
2:30 p.m.–3:15 p.m.
Are you looking for ways to be fulfilled in your personal life and work? Come explore your ikigai, or “reason for being,” and how to align your life with your passions and what feeds your soul.
Bollywood Dance
3:30 p.m.–4:15 p.m.
Join in and learn some Bollywood dance moves!
Top hits from the North American Neuro-Ophthalmology Society featured in today’s Society Spotlight
The AAN is partnering with the North American Neuro-Ophthalmology Society (NANOS) to bring Annual Meeting attendees updates on the cutting-edge science of neuro-ophthalmology from speakers giving encore presentations of top research presented at NANOS. The session will take place today from 1:00 p.m. to 3:00 p.m. in room 25C. Participants will hear about the most essential topics in neuroophthalmology disease, focusing on diagnosis and management and the latest updates and advancements.
Presentations and speakers include:
The Expanding Spectrum of Idiopathic Intracranial Hypertension (IIH)
Marc Dinkin, MD
1:00 p.m.–1:20 p.m.
Ocular Imaging for the Neurologist
Valerie Biousse, MD
1:20 p.m.–1:40 p.m.
The Many Faces of Optic Neuritis
Jeffrey L. Bennett, MD, PhD, FAAN
1:40 p.m.–2:00 p.m.
Double Vision and Dancing Eyes
Daniel R. Gold, DO
2:00 p.m.–2:20 p.m.
Billboard from the NANOS Meetings 2024 and 2025
Nancy J. Newman, MD, FAAN
2:20 p.m.–2:40 p.m.
Beyond the NANOS Meeting: Highlights of What’s to Come Nailyn Rasool, MD
2:40 p.m.–3:00 p.m.
The Neurology Career Center is your base for all things job hunting—and at the Annual Meeting, its booth is a favorite. Stop by the Sails Pavilion to check out the job board, get a copy of the Annual Meeting Job Guide, and learn more about how the Neurology Career Center can set you up for success. While you’re there, set up a job alert on Careers.AAN.com for a free “Neurology Is My Superpower” t-shirt while supplies last! Is
Recognizing the Signs and Symptoms of Friedreich Ataxia
Topic: This program will cover the pathophysiology of Friedreich ataxia (FA), key signs and symptoms, differential diagnoses, and genetic testing to confirm FA diagnosis, and is intended for neurologists and healthcare providers who are interested in learning more about FA.
Sunday, April 6, 2025
2:00 PM – 2:20 PM PST Exhibit Hall Presentation Stage
Featured Speaker: Alicia Henriquez, MD
Clinical Assistant Professor and Pediatric Neurologist at Seattle Children’s
Helpful Hints for Heroes Helpful Hints for Heroes
To reach these links in a flash, go to AAN.com/QuickLinks.
Attendee lunch
Grab your attendee lunch from 11:30 a.m.–1:30 p.m. and take time to explore the Exhibit Hall on its opening day. Lunches are served in compostable boxes to help with sustainability efforts.
Shuttle information
Scan the QR code to download routespecific shuttle schedules, access a 360-degree street view of the boarding location for each shuttle stop, and download a link to real-time shuttle wait times. Have questions? Call (877) 899-0986.
Program slides available online
Slides are available online only at AAN.com/Materials or through the AAN Conferences mobile app. You can access program materials through March 1, 2026. (Please note that availability of materials is at the discretion of the specific speaker. Not all sessions will have materials.)
Want more time to review programs?
Add Annual Meeting On Demand to your registration now to save up to 55% and to extend your access to session recordings through March 1, 2026. Check the back of your badge to see if you already have Annual Meeting On Demand. If not, head to registration or email aanamsupport@cmrus.com by May 7, 2025, to add it to your registration.
Submit evaluations for CME
Complete your evaluations by May 7, 2025 (or March 1, 2026, with Annual Meeting On Demand) to get your CME credits by using the AAN Conferences Mobile App or by visiting AAN.com/AMCME . Transcripts will be available upon evaluation submission. AAN members can also access their transcript via NeuroTracker™ at AAN.com/NeuroTracker. Enter your 6-digit ID and password to log in.
AANTV Studio
Stop by the AANTV Studio at the top of the escalators by Ballroom 20 (the Plenary Session room) to witness live interviews being recorded for later broadcast on the desktop platform, TV monitors around the convention center, AAN.com/AANTV, and YouTube.
Access past content
Conference attendees have access to content on the online platform through May 7, 2025. Visit AAN.com/AMOnline and use your 6-digit ID and password to log in. It may take up to 48 hours after course completion for content to become available online.
all conference guidelines at
Got a few minutes for fun between sessions? Get Neurology Question of the Day!
Whether you’re just waking up, in-between sessions, waiting for your food to arrive, or about to call it a night, if you’ve got a couple minutes to spare this week, then you’ve got time for the AAN’s free mobile app that serves up quick, convenient learning with minimal effort and maximum fun! Visit AAN.com/QOD today to download, then check out each day’s new question for the chance to earn up to two SA-CME per 25 questions answered.
Today’s Question:
An 18-year-old patient reports episodes of a bright zigzag line spreading across the visual field of both eyes with accompanying blurriness. Episodes resolve after 20 minutes and are often followed by a generalized throbbing headache with nausea and photophobia. Which of the following best describes the pathophysiology most likely responsible for the visual symptoms?
Answer options:
epileptiform discharges in the lingual gyrus inflammation of the subcortical white matter spreading depolarization of the occipital cortex
trigeminal nerve release of nociceptive neuropeptides
vasospasm of the intracranial arteries
Test your knowledge and choose the most appropriate answer by logging in or downloading the app today.
Join Robert Hauser, MD, MBA, FAAN and Stuart Isaacson, MD, FAAN as they discuss a NEW treatment for Parkinson’s.
Stuart Isaacson, MD, FAAN
Robert Hauser, MD, MBA, FAAN
WITH FIRDAPSE® (AMIFAMPRIDINE)
The recommended first-line therapy for patients living with Lambert-Eaton myasthenic syndrome (LEMS) 1
Visit us at Booth #807 to learn how FIRDAPSE is clinically proven to help patients maintain:
THE MAXIMUM TOTAL DAILY DOSE OF FIRDAPSE HAS INCREASED
Scan the code to learn about the dosing flexibility of this treatment
IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE:
FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.
Tom, living with LEMS
FIRDAPSE® (amifampridine) tablets for oral use
BRIEF SUMMARY OF FULL PRESCRIBING INFORMATION FOR FIRDAPSE
INDICATIONS AND USAGE
FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.
DOSAGE AND ADMINISTRATION
• Administer orally in divided doses (3 to 5 times daily).
• The recommended starting dosage for adults (any weight) and pediatric patients weighing 45 kg or more is 15 mg to 30 mg daily, in divided doses.
- Dosage can be increased by 5 mg daily every 3 to 4 days.
- The maximum single dose is 20 mg.
- Dosage is not to exceed a maximum of 100 mg daily.
• The recommended starting dosage for pediatric patients weighing less than 45 kg is 5 mg to 15 mg daily, in divided doses.
- Dosage can be increased by 2.5 mg daily every 3 to 4 days.
- The maximum single dose is 10 mg.
- Dosage is not to exceed a maximum of 50 mg daily.
CONTRAINDICATIONS
FIRDAPSE is contraindicated in patients with:
• A history of seizures
• Hypersensitivity to amifampridine phosphate or another aminopyridine
WARNINGS AND PRECAUTIONS
Seizures
FIRDAPSE can cause seizures. Seizures have been observed in patients without a history of seizures taking FIRDAPSE at the recommended doses, at various times after initiation of treatment, at an incidence of approximately 2%. Many of the patients were taking medications or had comorbid medical conditions that may have lowered the seizure threshold.
Seizures may be dose-dependent. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment.
Hypersensitivity
In clinical trials, hypersensitivity reactions and anaphylaxis associated with FIRDAPSE administration have not been reported. Anaphylaxis has been reported in patients taking another aminopyridine; therefore, it may occur with FIRDAPSE. If anaphylaxis occurs, administration of FIRDAPSE should be discontinued and appropriate therapy initiated.
ADVERSE REACTIONS
The following serious adverse reactions are described elsewhere in the labeling:
• Seizures
• Hypersensitivity
Clinical Trials Experience
Adults
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In controlled and uncontrolled trials (Study 1 and 2) in patients with LEMS, 63 patients were treated with FIRDAPSE, including 40 patients treated for more than 6 months, and 39 patients treated for more than 12 months. In an expanded access program, 139 patients with LEMS were treated with FIRDAPSE, including 102 patients treated for more than 6 months, 77 patients treated for more than 12 months, and 53 patients treated for more than 18 months.
Study 1 was a double-blind, placebo-controlled, randomized discontinuation study in adults with LEMS. Following an initial open-label run-in phase (up to 90 days), patients were randomized to either continue FIRDAPSE treatment or transition to placebo for a 14-day double-blind phase. Following final assessments, patients were allowed to resume FIRDAPSE treatment for up to 2 years (open-label, long-term safety phase of the study).
During the open-label run-in phase of Study 1, 53 patients received FIRDAPSE for an average of 81 days at an average daily dosage of 50.5 mg/day. The average patient age was 52.1 years and 66% were female. There were 42 patients who had no prior exposure to FIRDAPSE at the initiation of this study. Table 1 shows adverse reactions with an incidence of 5% or greater occurring in the 42 LEMS
patients newly initiated on treatment with FIRDAPSE during the run-in phase of the study.
Table 1. Adverse Reactions in ≥5% of LEMS Patients Newly Treated with FIRDAPSE in Study 1
*Includes paresthesia, oral paresthesia, oral hypoesthesia
**Includes elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and gamma-glutamyl transferase (GGT)
Other Adverse Reactions
In the overall population treated in Study 1 (n=53), including the double-blind phase and the 2-year open-label long-term safety phase, additional adverse reactions occurring in at least 5% of the patients included: dyspnea, urinary tract infection, gastroesophageal reflux, insomnia, peripheral edema, pyrexia, viral infection, blood creatine phosphokinase increase, depression, erythema, hypercholesterolemia, and influenza. These patients received an average daily dosage of 66 mg of FIRDAPSE.
Pediatrics
Safety of FIRDAPSE was evaluated in pediatric patients in an expanded access program, where 21 pediatric patients received FIRDAPSE for at least 1 year. Adverse reactions reported in pediatric patients were similar to those seen in adult patients, with the exception of clinically significant weight loss in two pediatric patients at doses of 60 mg per day and higher.
DRUG INTERACTIONS
Drugs that Lower Seizure Threshold
The concomitant use of FIRDAPSE and drugs that lower seizure threshold may lead to an increased risk of seizures. The decision to administer FIRDAPSE concomitantly with drugs that lower the seizure threshold should be carefully considered in light of the severity of the associated risks.
Drugs with Cholinergic Effects
The concomitant use of FIRDAPSE and drugs with cholinergic effects (e.g., direct or indirect cholinesterase inhibitors) may increase the cholinergic effects of FIRDAPSE and of those drugs and increase the risk of adverse reactions.
USE IN SPECIFIC POPULATIONS
Pregnancy
Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to FIRDAPSE during pregnancy. Physicians are encouraged to enroll pregnant patients, or pregnant women may register themselves in the registry by calling 855-212-5856 (toll-free), using the Fax number 877-867-1874 (toll-free), by contacting the Pregnancy Coordinating Center at
Please see FIRDAPSE Brief Summary above and scan the QR code for full Prescribing Information.
firdapsepregnancyregistry@ubc.com or by visiting the study website at www.firdapsepregnancystudy.com.
Risk Summary
There are no data on the developmental risk associated with the use of FIRDAPSE in pregnant women. In animal studies, administration of amifampridine phosphate to rats during pregnancy and lactation resulted in developmental toxicity (increase in stillbirths and pup deaths, reduced pup weight, and delayed sexual development) at doses associated with maternal plasma drug levels lower than therapeutic drug levels (see Animal Data). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.
Data
Animal Data
Oral administration of amifampridine phosphate (0, 7.5, 22.5, or 75 mg/kg/day) to female rats prior to and during mating and continuing throughout organogenesis produced no adverse effects on embryofetal development. Plasma amifampridine exposure (AUC) at the highest dose tested is approximately 7 times that in humans at the maximum recommended human dose (MRHD) of 80 mg amifampridine/day. Oral administration of amifampridine phosphate (0, 9, 30, or 57 mg/kg/day) to pregnant rabbits throughout organogenesis produced no adverse effects on embryofetal development. The highest dose tested is approximately 7 times the MRHD (80 mg/day amifampridine) on a body surface area (mg/m2) basis.
Oral administration of amifampridine phosphate (0, 7.5, 22.5, or 75 mg/kg/day) to female rats throughout pregnancy and lactation resulted in an increase in stillbirths and pup deaths, reduced pup weight, and delayed sexual development in female pups at the mid and high doses tested. The no-effect dose (7.5 mg/kg/day amifampridine phosphate) for adverse developmental effects is associated with a plasma amifampridine exposure (AUC) less than that in humans at the MRHD.
Lactation
Risk Summary
There are no data on the presence of FIRDAPSE in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for FIRDAPSE and any potential adverse effects on the breastfed infant from FIRDAPSE or from the underlying maternal condition.
In lactating rat, amifampridine was excreted in milk and reached levels similar to those in maternal plasma.
Pediatric Use
Safety and effectiveness of FIRDAPSE for the treatment of LEMS have been established in pediatric patients 6 years of age and older.
Use of FIRDAPSE for this indication is supported by evidence from adequate and well-controlled studies of FIRDAPSE in adults with LEMS, pharmacokinetic data in adult patients, pharmacokinetic modeling and simulation to identify the dosing regimen in pediatric patients, and safety data from pediatric patients aged 6 years and older.
Safety and effectiveness in pediatric patients below the age of 6 years have not been established.
Geriatric Use
Clinical studies of FIRDAPSE did not include sufficient numbers of subjects aged 65 and over (19 of 63 patients in Studies 1 and 2) to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Renal Impairment
Renal clearance is an elimination pathway for amifampridine and the inactive metabolite, 3-N-acetyl amifampridine, and exposure of amifampridine is higher in subjects with renal impairment. Therefore, in patients with renal impairment, FIRDAPSE should be initiated at the lowest recommended initial daily dosage, and patients should be
closely monitored for adverse reactions. Consider dosage modification or discontinuation of FIRDAPSE for patients with renal impairment as needed based on clinical effect and tolerability. The safety, efficacy, and pharmacokinetics of amifampridine have not been studied in patients with endstage renal disease (CLcr <15 mL/min or patients requiring dialysis). No dosage recommendation for FIRDAPSE can be made for patients with end-stage renal disease.
Hepatic Impairment
In patients with any degree of hepatic impairment, FIRDAPSE should be initiated at the lowest recommended initial daily dosage, and patients should be monitored for adverse reactions. Consider dosage modification or discontinuation of FIRDAPSE for patients with hepatic impairment as needed based on clinical effect and tolerability.
NAT2 Poor Metabolizers
Exposure of FIRDAPSE is increased in patients who are N-acetyltransferase 2 (NAT2) poor metabolizers. Therefore, initiate FIRDAPSE in patients who are known NAT2 poor metabolizers at the lowest recommended initial daily dosage and monitor for adverse reactions. Consider dosage modification of FIRDAPSE for patients who are known NAT2 poor metabolizers as needed based on clinical effect and tolerability.
PATIENT COUNSELING INFORMATION
Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide).
Risk of Seizures
Inform patients that FIRDAPSE can cause seizures, and to notify their healthcare provider if they experience a seizure.
Hypersensitivity
Instruct patients to inform their healthcare provider if they have signs or symptoms of hypersensitivity, and to seek emergency help if symptoms of anaphylaxis occur.
FIRDAPSE Dosing
Instruct patients to take FIRDAPSE exactly as prescribed.
Patients should carefully follow the dose escalation schedule provided by their healthcare provider to safely achieve the therapeutic dosage. Inform patients that the tablets may be divided in half at the score, if needed. Instruct patients not to take a double dose to make up for a missed dose.
If they require a dosage in less than 5 mg increments, have difficulty swallowing tablets, or require feeding tubes, refer patients and/or caregivers to the Instructions for Use on how to prepare a 1 mg/mL suspension. If the patient requires treatment with the 1 mg/mL FIRDAPSE suspension, advise patients and/or caregivers that supplies required to prepare the suspension may be obtained at their local pharmacy.
Drug Interactions
Instruct patients to notify their healthcare provider prior to starting any new medication, including over-the-counter drugs.
Pregnancy
Instruct patients that if they are pregnant or plan to become pregnant while taking FIRDAPSE they should inform their healthcare provider. Advise patients that there is a pregnancy registry that monitors pregnancy outcomes in women exposed to FIRDAPSE during pregnancy and encourage them to enroll if they become pregnant while taking FIRDAPSE
Storage
Advise patients to store FIRDAPSE at 68°F to 77°F (20°C to 25°C). Instruct patients and/or caregivers who prepare the 1 mg/ mL suspension of FIRDAPSE that it should be prepared daily and refrigerated between doses. The suspension can be stored under refrigeration for up to 24 hours. Instruct the patient and/or caregiver to discard any unused portion of the suspension after 24 hours.
Distributed by Catalyst Pharmaceuticals, Inc., Coral Gables, FL 33134.
FIRDAPSE® is a registered trademark of SERB S.A. © 2025 Catalyst Pharmaceuticals, Inc. All Rights Reserved.
References: 1. Yoon CH, Owusu-Guha J, Smith A, Buschur P. Amifampridine for the management of LambertEaton myasthenic syndrome: a new take on an old drug. Ann Pharmacother. 2020;54(1):56-63. 2. Full Prescribing Information for FIRDAPSE (amifampridine). Catalyst Pharma; 2024. 3. Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, et al; LEMS Study Group. Amifampridine phosphate (FIRDAPSE®) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve. 2016;53(5):717-725. 4. Shieh P, Sharma K, Kohrman B, Oh SJ. Amifampridine phosphate (FIRDAPSE) is effective in a confirmatory phase 3 clinical trial in LEMS. J Clin Neuromuscul Dis. 2019;20(3):111-119.
LEARN HOW TO LOOK FOR THIS RARE DISEASE EARLIER
LEMS (Lambert-Eaton myasthenic syndrome) is a progressive disorder—the longer an individual remains undiagnosed and untreated, the greater their burden of disease and the worse their quality of life.1
Why is LEMS difficult to identify?
While some of the advanced signs of LEMS—such as severe muscle weakness2, unsteady gait1,3, and ocularbulbar symptoms2,4-6—can be easy to spot, deciphering the early signs of LEMS can be challenging.
Scan this code to learn about distinguishing the signs and uncovering LEMS in your practice
References: 1. Harms L, Sieb J-P, Williams AE, et al. Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndrome: results of a patient interview survey in Germany. J Med Econ. 2012;15(3):521-530. 2. Merino-Ramírez MÁ, Bolton CF. Review of the diagnostic challenges of Lambert-Eaton syndrome revealed through three case reports. Can J Neurol Sci . 2016;43(5):635-647. 3. National Organization for Rare Disorders. Rare disease database: Lambert-Eaton myasthenic syndrome. Accessed July 25, 2024. https://rare-diseases.org/rare-diseases/lambert-eaton-myasthenic-syndrome/. 4. Young JD, Leavitt JA. Lambert-Eaton myasthenic syndrome: ocular signs and symptoms. J Neuroophthalmol. 2016;36(1):20-22. 5. Titulaer JM, Wirtz PW, Wintzen AR, Verschuuren JJGM. Lambert-Eaton myasthenic syndrome with pure ocular weakness. Neurology . 2008;70(1):86-87. 6. Gordon LK. Paraneoplastic syndromes in neuro-ophthalmology. J Neuroophthalmol . 2015;35(3):306-314.
© 2025 Catalyst Pharmaceuticals, Inc. All Rights Reserved.
LEM-0483-1 February 2025
Keep the CME rolling: get 15% off Continuum®!
Get connected with Section Showcases or a Section Poster Tour!
AAN sections provide more than 40 vibrant, member-led online communities in a wide range of subspecialties and interests—and at the Annual Meeting, many of them connect in person. Attend a Section Showcase session or a Section Poster Tour to meet other neurology professionals and hear the latest updates in the field!
Continuum: Lifelong Learning in Neurology® is the go-to source of updated, in-depth clinical review information and CME for neurology professionals. It’s kind of like having a patient care superpower! Subscribe or renew now to save 15% off the regular rate—an alreadyreduced $399/year for AAN members—with the spring special, and lock in your savings for up to three years.
Visit the AAN Publications booth in the Sails Pavilion for details!
Section Showcases highlight the great work of more than 15 of the AAN’s sections, with today’s offerings including discussions on antisense oligonucleotides in neurogenetics, international guidelines on neurological infections, and autonomic symptom assessment and treatment in movement disorders. Search “Section Showcase” in the desktop platform or mobile app to find one that interests you!
Sections will also lead poster tours during the Annual Meeting, providing a collaborative chance to see the latest research. Search “Section Poster Tour” in the desktop platform or mobile app to see the full schedule. Interested in joining a section?
Any AAN member can join sections. When you connect, you’ll have access to that section’s community on Synapse, available online and through the SynapseSM Member Communities app. Learn more and see a full list at AAN.com/sections.
Today’s Neuroscience in the Clinic session covers regenerative rehabilitation
Regenerative rehabilitation is the focus of today’s Neuroscience in the Clinic, which will take place from 3:30 p.m. to 5:30 p.m. in 25B. Directors Paul M. George, MD, PhD, MSE, FAAN, and Fabrisia Ambrosio, PhD, will be joined by expert faculty Sean I. Savitz, MD; Robert Gaunt, PhD; and Stefania Corti, MD, PhD, to discuss methods to improve neural recovery by combining approaches from regenerative and rehabilitative medicine. Faculty will discuss how we understand the recovering neural environment after injury and how we examine the power of combining regenerative techniques such as stem cells and endogenous injury mechanisms with methods to enhance these reparative processes.
“Our session addresses the compelling question of how we can improve healing the nervous system after injury,” said George. “Given the complexity of the brain and nervous system, patients are often left with lasting neurological deficits after injury. This session delves into how we likely need to combine multiple approaches to cause lasting recovery. The session will provide the latest advances and current state of the approaches to help patients recover after neural injury.”
The session will conclude with a panel discussion along with opportunity for questions. Attendees may claim two CME credits.
George Ambrosio
Savitz
Gaunt
Corti
VOICES OF THE ANNUAL MEETING
How many Annual Meetings have you attended?
I have no clue… 30, probably 40. I’ve been a neurologist for almost 50 years.
What keeps bringing you back to our meeting?
It’s a time to reengage with colleagues, particularly those from afar, and exchange ideas. It’s a large meeting and one can’t see it all, but it’s a very vibrant time to learn new things, engage with colleagues, and meet new colleagues.
James F. Howard, Jr., MD, FAAN
Is there anything you’re particularly excited for at the Annual Meeting?
Everything. I’m a medical student, second year, and I’m very excited about neurology—so to me, being here is a realization of my dream.
What have you enjoyed so far?
The (Controversies in Neurology) plenary was very fun. I’m very excited for my presentation, too!
Rebeca Silva
Have you been to the Annual Meeting before?
I was at Denver last year, so it’s my second.
What are you looking forward to this year?
This is my fellowship year, so I’m looking forward to catching up with a lot of my friends from residency, and I’m attending some of the sessions for updates just to make sure I keep abreast of all of the developments in the field that aren’t in my subspecialty.
Kevin Yan, MD
AAN family of podcasts
Where in the world is your SIGN from?
There are more than 150 Student Interest Group in Neurology (SIGN) chapters in the world. If you’re part of one of them, put it on the world map at the Trainee Hub!
Are you a medical student but not a SIGN member—yet? Go to AAN.com/SIGN to learn more, see if your school has a chapter, or start a new one.
2025 Service Award Recipients
ASSOCIATION OF INDIAN NEUROLOGISTS IN AMERICA
LIFETIME ACHIEVEMENT AWARD
Sponsored by the Association of Indian Neurologists in America Fund of the American Brain Foundation.
Jai Kumar, MD, FACP, FAAN Garland, TX
CHANGEMAKER AWARD
Sponsored by the American Academy of Neurology.
Charles C. Flippen II, MD, FAAN
UCLA David Geffen School of Medicine, Los Angeles, CA
GENERAL NEUROLOGY AWARD
Sponsored by the American Academy of Neurology.
Richard Cuneo, MD
University of California, San Francisco, San Francisco, CA
KENNETH M. VISTE JR., MD, PATIENT ADVOCATE OF THE YEAR AWARD
Sponsored by the American Academy of Neurology and endowed by gifts from Dr. Viste’s colleagues, friends, and patients.
Kapil Arya, MBBS, DA, FAAP, FACNS, FAAN University of Arkansas for Medical Sciences, Little Rock, AR
MRIDHA SPIRIT OF NEUROLOGY HUMANITARIAN AWARD
Sponsored by the American Brain Foundation and endowed by gifts to the Dr. Debasish and Chinu Mridha Endowment Fund.
Monica Diaz, MD, MS University of North Carolina, Chapel Hill, NC
Melissa Elafros, MD, PhD University of Michigan, Ann Arbor, MI
Rajesh Shankar Iyer, MD, DM Kovai Medical Center and Hospitals, Coimbatore, Tamil Nadu, India
NEUROLOGY PRACTICE AWARD
Sponsored by the American Academy of Neurology.
Neurology One Orlando, FL
TED BURNS HUMANISM IN NEUROLOGY AWARD
Sponsored by the American Brain Foundation. Mehari Gebreyohanns, MD, FAHA, FAAN UT Southwestern Medical Center, Dallas, TX VOLUNTEER SERVICE AWARD
Sponsored by the American Academy of Neurology.
Nirmal Surya, MD, DNB, FAAN Surya Neuro Centre, Mumbai, India
TERRENCE L. CASCINO AWARD FOR PHYSICIAN LEADERSHIP
Jennifer Bickel, MD, FAAN University of Texas MD Anderson Cancer Center, Houston, TX
LEADING IN EXCELLENCE THROUGH MENTORSHIP
James C. Stevens, MD, FAAN Fort Wayne Neurological Center, Fort Wayne, IN
Pioneering Gene Therapy in Neurodegenerative Disease
Our goal is to use the advanced technology of gene therapy to impact disease progression in individuals with Parkinson’s disease and multiple system atrophy. Gene therapy may provide neuroprotection and neurorestoration of dopaminergic neurons.
Visit UCNS booth for details on subspecialty certification and accreditation
Stop by booth 611 in the exhibit hall to learn about neurological subspecialty physician certification and accredited fellowship program opportunities through the United Council for Neurologic Subspecialties (UCNS). As neurology’s recognized certifying and accrediting body for emerging subspecialties, the UCNS currently provides accreditation and/or certification for the neurological subspecialties of Autonomic Disorders, Behavioral Neurology & Neuropsychiatry, Clinical Neuromuscular Pathology, Geriatric Neurology, Headache Medicine, Interventional Neurology, Neonatal Neurocritical Care, Neuroimaging, Neurocritical Care, and Neuro-oncology. The UCNS currently has 245 accredited fellowship programs and over 3,300 certified physicians in the United States and Canada.
Staff will be on hand in the booth to share information and answer questions about UCNS certification, continuous certification requirements, fellowship program accreditation requirements, and accredited subspecialty fellowship opportunities.
The UCNS will also have representatives available at the Trainee and Faculty Reception on Monday, April 7, from 6:00 p.m. to 8:00 p.m. at the Marriott Marquis San Diego Marina to answer questions and provide information for trainees about UCNS-accredited subspecialty fellowship programs.
Solutions
Innovation in generalized myasthenia gravis (gMG), backed by a history of excellence in neurology
UCB is excited to share more about recent advancements for adults living with gMG.
Two targeted treatments. Many possibilities. Join us at booth #1621
Learn about our unique portfolio of treatments targeting different pathways in gMG.